4,901 trials
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
Ranitidine Adverse Reaction · Pharmacokinetics · Food-drug Interaction
Primary: Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo) — 0.6; 10.5; 11.9; 23.4 nanograms — p=0.54
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
Type2 Diabetes Mellitus
Primary: Digoxin Cmax (Maximum Observed Plasma Concentration) — 2.315; 2.301 ng/mL
Hemophilia A · Hemophilia B · Hemophilia A With Inhibitor
Primary: Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last — 1390.0; 516.4; 849.4; 1060.0 h*ng/mL
Retinal Disease · Retinitis Pigmentosa
Primary: Systemic and Ocular Safety — 0; 0; 1; 0 Participants
Diabetes Mellitus, Type 2
Primary: Gliclazide AUC — 3.73; 3.29 μgh/mL
Cancer · Neoplasm
Primary: Number of Patients With NY-ESO-1 Specific Humoral Immunity as Determined by an Increase in Antibody Titer From Baseline. — 8; 5; 1 Participants
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Myelodysplastic Syndrome · Multiple Myeloma · Hodgkin Lymphoma
Primary: Number of Participants Who Experienced One or More Adverse Events (AEs): — 27; 28; 31; 21 Participants
Pharmacokinetics
Primary: Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose — 366.6; 385.3; 697.4 ng/mL
Pediculosis
Primary: Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF — -9.7; -9.2; 6.1 milliseconds
Malaria
Primary: Number of Participant With Treatment-Related Adverse Events as Assessed by CTCAE V4.03, All of Observed and Self-reported AEs Affected, by Treatment Regimen. — 6; 2…
Alzheimer's Disease (AD)
Primary: Number of Dose Limiting Toxicity Events — 0; 0 Dose Limiting Toxicity Events
Healthy Japanese Participants
Primary: Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil — 1029; 833.6; 721.3 ng/mL